Here are five points:
1. The company raised $15 million during the financing round.
2. The investment was led by Haisco Pharmaceutical Group, a Chinese pharmaceutical manufacturer.
3. The investment will be used primarily for conducting a pivotal clinical trial on Regentis Biomaterials’ GelrinC in the United States.
4. GelrinC is a proprietary hydrogel-based product. It is implanted as a liquid and is cured in-situ to form a resorbable implant.
5. It is intended for patients suffering from cartilage injuries.
More articles on devices:
Stryker buys Physio-Control for $1.28B in 3rd February 2016 acquisition: 6 key note
Medtech sells ROSA system in France: 3 things to know
Quantitative Systematic Strategies ups stake in NuVasive stock by 148.9%: 5 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
